Open questions
These pages list research questions about menopause, skin, hair and mucosa that science has not settled yet. They are not advice, not a shop and not a clinic.
Talk to your own doctor about your situation. These pages describe the state of research, not what fits you.
Open questions began with 9 questions on skin, hair, mucosa and how menopause research is done.
Status legend
- Open: no well designed human study answers the main question yet.
- Contested: strong sources disagree on the main outcome. We cite both sides.
- Partly answered: a trial or systematic review answers part of the question. We name the part that is still open.
How these labels are set: see #how-status-works.
The questions
Skin, hair and mucosa
How menopause research is done
| ID | Question | Status | Last reviewed |
|---|---|---|---|
| OQ-03 | Do findings from thigh, hip or abdominal skin studies apply to the face? | Open | 2026-10-12 |
| OQ-08 | Are treatments as effective and safe in perimenopause as after menopause? | Open | 2026-10-12 |
| OQ-09 | Can any test reliably tell where a person is in the menopause transition? | Open | 2026-10-12 |
| OQ-10 | Do menopause symptoms and treatment effects differ across ethnic groups and countries? | Open | 2026-10-12 |
Related midlife research questions
Coming in a later wave.
The ID OQ-07 is reserved. A question on menopausal itch did not reach our three source minimum, so it has no page. The ID will not be reused for a different question.
What changed this quarter
No status changes this quarter.
Research bottlenecks
These are some of the reasons questions stay open. They are not ranked.
- There are no approved effective treatments to prevent or ease skin changes linked to estrogen deficiency, and many questions remain unanswered. (Merzel Sabovic 2024, https://doi.org/10.1177/20533691241233440)
- Much skin research samples covered hip or buttock skin, and one study found a hormone effect on hip skin but not on sun damaged skin. (Rittie 2008, https://doi.org/10.1001/archderm.144.9.1129)
- Some key skin studies are small: one ceramide study compared groups of 7, 11 and 10 women. (Kendall 2022, https://doi.org/10.1038/s41598-022-26095-0)
- Trials of mixed skin products cannot show which ingredient did what. (Na Takuathung 2023, https://doi.org/10.3390/jcm12041326)
- Registry studies on vaginal estrogen after breast cancer measure different outcomes, so their results are hard to compare. (Mainar 2026, https://doi.org/10.1016/j.maturitas.2026.108914)
- Data on hormone therapy for menopausal hair loss are limited and inconsistent, and longitudinal studies are missing. (Roster 2026, https://doi.org/10.1007/s40257-025-00994-0)
- Markers of the menopause transition give probabilities for groups, not certainty for a person. (Finkelstein 2020, https://doi.org/10.1210/clinem/dgz283)
- In low and middle income countries, only 4% of studies were nationally representative. (Islam 2025, https://doi.org/10.1080/13697137.2025.2509254)
How status works
Every question has one of three labels: open, contested or partly answered. A label changes only after a new peer reviewed trial, an updated systematic review, a major guideline change or a change by a drug regulator. Press releases, conference talks, preprints, animal studies and single small studies do not change a label.
Our editorial team drafts any change, our claim gate checks it, and the publisher approves it. Every change is dated, gets a new version number and appears in the changelog at /open-questions/changelog. Full rules: /methodology#open-questions.
Independence and how these pages are made
MenoDerm is run by Fabrick Asset Investments GmbH. We sell no products on these pages and have no sponsors. Drafts are written with the help of AI agents. People then check every page in an editorial review and a claim gate. Every source is looked up by its DOI and matched to its title, first author and year before we cite it.
Editorial review and claim gate, no external clinical review.
Spotted an error? Our corrections route is described on /methodology.